<DOC>
	<DOCNO>NCT00876655</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( PK ) 2 different TR-701 oral formulation ( free acid phosphate powder capsule di-sodium phosphate salt formulate capsule ) single dos normal healthy adult subject assess relative bioavailability TR-701 free acid phosphate powder capsule formulation compare di-sodium phosphate salt formulate capsule .</brief_summary>
	<brief_title>Exploratory Pharmacokinetic Bioavailability Study 2 Capsule Formulations Torezolid Phosphate</brief_title>
	<detailed_description>Subjects receive follow treatment crossover design : Treatment A ( Reference ) : One 200 mg capsule TR-701 di-sodium phosphate salt ( equivalent 150 mg TR-700 ) administer orally least 8-hour fast 240 mL room temperature water ; Treatment B ( Test ) : One 182 mg capsule TR-701 free acid phosphate ( equivalent 150 mg TR-700 ) administer orally least 8-hour fast 240 mL room temperature water ; Descriptive statistic calculate PK parameter include Cmax , Tmax , AUC0-t , AUC0-inf .</detailed_description>
	<mesh_term>Torezolid phosphate</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<criteria>In good health , determine clinically significant finding medical history , physical examination , 12lead ECG , vital sign ; Females nonpregnant , nonlactating , either postmenopausal least 1 year , surgically sterile least 90 day , agree use acceptable form contraception BMI 18.5 32.0 kg/m2 , inclusive Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History significant hypersensitivity , intolerance , allergy drug compound , food , substance Pregnancy , lactation , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>